Pyrazoline analogs as potential anticancer agents and their apoptosis, molecular docking, MD simulation, DNA binding and antioxidant studies
- PMID: 33571809
- DOI: 10.1016/j.bioorg.2021.104665
Pyrazoline analogs as potential anticancer agents and their apoptosis, molecular docking, MD simulation, DNA binding and antioxidant studies
Abstract
N-formyl pyrazoline derivatives (3a-3l) were designed and synthesized via Michael addition reaction through cyclization of chalcones with hydrazine hydrate in presence of formic acid. The structural elucidation of N-formyl pyrazoline derivatives was carried out by various spectroscopic techniques such as 1H, 13C NMR, FT-IR, UV-visible spectroscopy, mass spectrometry and elemental analysis. Anticancer activity of the pyrazoline derivatives (3a-3l) was evaluated against human lung cancer (A549), fibrosarcoma cell lines (HT1080) and human primary normal lung cells (HFL-1) by MTT assay. The results of anticancer activity showed that potent analogs 3b and 3d exhibited promising activity against A549 (IC50 = 12.47 ± 1.08 and 14.46 ± 2.76 µM) and HT1080 (IC50 = 11.40 ± 0.66 and 23.74 ± 13.30 µM) but low toxic against the HFL-1 (IC50 = 116.47 ± 43.38 and 152.36 ± 22.18 µM). The anticancer activity of potent derivatives (3b and 3d) against A549 cancer cell line was further confirmed by flow cytometry based approach. DNA binding interactions of the pyrazoline derivatives 3b and 3d have been carried out with calf thymus DNA (Ct-DNA) using absorption, fluorescence and viscosity measurements, circular dichroism and cyclic voltammetry. Antioxidant potential of N-formyl pyrazoline derivatives (3a-3l) has been also estimated through DPPH (2,2-diphenyl-1-picrylhydrazyl) free radical and H2O2. Results revealed that all the compounds exhibited significant antioxidant activity. In silico molecular modelling and ADMET properties of pyrazoline derivatives were also studied using PyRx software against topoisomerase II receptor with PDB ID: 1ZXM to explore their best hits. MD simulation of 3b and 3d was also carried out with topoisomerase II for structure-function correlation in a protein. HuTopoII inhibitory activity of the analogs (3a-3l) was examined by relaxation assay at varying concentrations 100-1000 µM.
Keywords: Anticancer; Antioxidant; Ct-DNA; MD simulations; Molecular modelling; N-formyl pyrazoline.
Copyright © 2021 Elsevier Inc. All rights reserved.
Similar articles
-
Novel dihydrobenzofuran derivatives: design, synthesis, cytotoxic activity, apoptosis, molecular modelling and DNA binding studies.J Biomol Struct Dyn. 2024;42(23):12742-12760. doi: 10.1080/07391102.2023.2273431. Epub 2023 Oct 30. J Biomol Struct Dyn. 2024. PMID: 39612190
-
Design and Synthesis of Carbothioamide/Carboxamide-Based Pyrazoline Analogs as Potential Anticancer Agents: Apoptosis, Molecular Docking, ADME Assay, and DNA Binding Studies.ACS Omega. 2022 Jun 23;7(26):22639-22656. doi: 10.1021/acsomega.2c02033. eCollection 2022 Jul 5. ACS Omega. 2022. PMID: 35811873 Free PMC article.
-
Synthesis of 1-acetyl-3-(2-thienyl)-5-aryl-2-pyrazoline derivatives and evaluation of their anticancer activity.J Enzyme Inhib Med Chem. 2013 Dec;28(6):1221-7. doi: 10.3109/14756366.2012.724682. Epub 2012 Oct 1. J Enzyme Inhib Med Chem. 2013. PMID: 23020635
-
Pyrazoline Hybrids as Promising Anticancer Agents: An Up-to-Date Overview.Int J Mol Sci. 2020 Jul 31;21(15):5507. doi: 10.3390/ijms21155507. Int J Mol Sci. 2020. PMID: 32752126 Free PMC article. Review.
-
Diverse Pharmacological Potential of different Substituted Pyrazole Derivatives.Curr Org Synth. 2024;21(7):858-888. doi: 10.2174/0115701794260444230925095804. Curr Org Synth. 2024. PMID: 37861007 Review.
Cited by
-
Rational Design, Synthesis and Biological Evaluation of Novel Pyrazoline-Based Antiproliferative Agents in MCF-7 Cancer Cells.Pharmaceuticals (Basel). 2022 Oct 10;15(10):1245. doi: 10.3390/ph15101245. Pharmaceuticals (Basel). 2022. PMID: 36297358 Free PMC article.
-
Comprehensive Insight into Green Synthesis Approaches, Structural Activity Relationship, and Therapeutic Potential of Pyrazolic Chalcone Derivative.Mini Rev Med Chem. 2025;25(7):539-577. doi: 10.2174/0113895575327555241024111038. Mini Rev Med Chem. 2025. PMID: 39513315 Review.
-
3,5-Disubstituted pyrazoline as a promising core for anticancer agents: mechanisms of action and therapeutic potentials.Future Med Chem. 2025 Mar;17(6):725-745. doi: 10.1080/17568919.2025.2476393. Epub 2025 Mar 13. Future Med Chem. 2025. PMID: 40079157 Review.
-
Design, synthesis, X-ray crystal structures, anticancer, DNA binding, and molecular modelling studies of pyrazole-pyrazoline hybrid derivatives.RSC Adv. 2023 Sep 6;13(38):26766-26779. doi: 10.1039/d3ra04873j. eCollection 2023 Sep 4. RSC Adv. 2023. PMID: 37681049 Free PMC article.
-
The Synthesis, In Vitro Bio-Evaluation, and In Silico Molecular Docking Studies of Pyrazoline-Thiazole Hybrid Analogues as Promising Anti-α-Glucosidase and Anti-Urease Agents.Pharmaceuticals (Basel). 2023 Nov 25;16(12):1650. doi: 10.3390/ph16121650. Pharmaceuticals (Basel). 2023. PMID: 38139777 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical